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Groups offemale SENCAR or BALB/c mice were initiated once intraperitoneally with 300 jig/mouse of
7,12-dimethylbenz(a)anthracene (DMBA) or 20 mg/mouse of urethane at 7 weeks of age. Beginning one
week later, mice received topically applied acetone or 12-O-tetradecanoylphorbol-13-acetate (TPA), once
weekly, at 2.5 ,g/mouse for weeks 1 through 6 and 1.25 ,ug/mouse for weeks 7 through 52. The skin lesions
were evaluated clinically. A complete necropsy was performed on all mi¢e at week 52. SENCAR mice
exposed to DMBA/TPA and urethane/TPA had more skin tumors than SENCAR mice exposed to DMBA
or urethane alone and more than BALB/c mice in any treatment group. Of ill skin carcinomas diagnosed
histologically in DMBA/TPA-exposed mice, less than one-third had been identified clinically while the
mice were alive. Most of the carcinomas arose within papillomas. BALB/c mice developed more vascular
and uterine tumors than did SENCAR mice injected with DMBA and more lung and vascular tumors than
did SENCAR mice injected with urethane. TPA exposure after treatment with either initiator had no
significant effect on internal tumor development in either SENCAR or BALB/c mice.
Introduction
SENCAR mice wereoriginallybred forsusceptibility
to two-stage carcinogenesis in mouse skin (1). It has
been demonstrated that these mice are exceptionally
more sensitive to skin carcinogenesis by chemicals (2-
4) and by ultraviolet irradiation (5) than most other
strains or stocks ofmice, and that SENCAR mice have
a population ofspontaneously initiated cells (3), as well
as dark cells (2), which are possible targets of carcin-
ogens. An earlier study of two-stage carcinogenesis in
SENCAR and BALB/c mice has shown that SENCAR
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mice are considerablymore sensitivethan BALB/cmice
(3) to two-stage carcinogenesis. The aim ofthis current
study was to evaluate the differential carcinogenic ef-
fects of 7,12-dimethylbenz(a)anthracene (DMBA) and
urethane on internal tumor development in female
SENCAR and BALB/c mice and to observe the effects
of a skin tumor promoter, topically applied 12-0-tetra-
decanoylphorbol-13-acetate (TPA), on development of
both epidermal and nonepidermal neoplasms,
Materials and Methods
Animals
Two hundred female SENCAR mice (Oak Ridge Na-
tional Laboratories, Oak Ridge, TN) and two hundred
female BALB/c mice (Charles River Breeding Labo-
ratories, Wilmington, MA) were received and held until
they were 7 weeks of age, at which time they wereWARD ET AL.
Table 1. Experimental design: the carcinogenicity of DMBA,
urethane, and TPA in SENCAR and BALB/c mice.
Strain
or stock
SENCAR
No. of
mice
intitiated
15
15
15
15
30
30
30
30
BALB/c 15
15
15
15
30
30
30
0 Initiato/S
0.25 mL DMSO/SSV
0.25 mL DMSO/SSV
0.25 mL Saline
0.25 mL Saline
DMBA (300 ,g in
0.25 mL DMSO/SSV)
Pt
Urethane (20 mg in
0.25 mL saline) 0S
0.25 mL DMSO/SSV
0.25 mL DMSO/SSV
0.25 mL Saline
0.25 mL Saline
DMBA (300 ±g in
0.25 mL DMSO/SSV)
it
Urethane (20 mg in
0.25 mL saline)
Promoterb
Acetone
TPA
Acetone
TPA
Acetone
TPA
Acetone
TPA
Acetone
TPA
Acetone
TPA
Acetone
TPA
Acetone
16 30 " TPA
aOnce intraperitoneally at 7 weeks of age.
bOnce per week, 0.2 mL topically, 2.5 ,ug ofTPA from weeks 1 to
6 and 1.25 ,ug of TPA from weeks 7 to 52.
initiated. All animals were housed 5 per 7 in. x 11.5
in. polyearbonate cage on 1/8 in. corn cob bedding, ac-
cording to strain and treatment. Water and Purina Lab
Chow were available ad libitum throughout the exper-
iment. All water bottles and cages were changed and
sanitized twice per week, the adequacy of food and
water was checked daily, and death checks were per-
formed twice daily.
SENCAR
DMBA
55
50
E
2
I.-
45
40
35
30
25
20
15
SENCAR
DMBA. PA
Chemicals
Initiators. DMBA was purchased from Eastman
Organic (Rochester, NY) and prepared as a solution of
1,200 pRg/mL in a dimethyl sulfoxide (DMSO) steroid
suspending vehicle (SSV) (10%/90%). The DMBA was
first dissolved in the appropriate volume of DMSO
(Pierce Chemicals, Rockford, IL) and then diluted with
ninetimesthevolumeofSSV(NationalCancerInstitute
[NCI], Cancer Chemotherapy Branch). Urethane pur-
chased from Matheson, Coleman and Bell (Norwood,
OH) was prepared as a solution of 80 mg/mL in sterile
saline.
Working solutions ofboth carcinogens were prepared
in yellow light under a hood, contained in amber mul-
tidose serum vials, and administered immediately after
preparation to the animals. DMBA stocks used for dose
preparations were stored at -20°C over Drierite in am-
ber glass vials; urethane stocks used for dose prepa-
rations were stored at room temperature in foil-
wrapped vessels.
Promoter. TPA purchased from CCR Inc. (Eden
Prairie, MN) was prepared as a 12.5 ,ug/mL or 6.25 jig/
mL solution in acetone (Baker Chemical, Reagent
Grade) depending on the dose to be given. Stock solu-
tions of TPA were kept in tightly stoppered glass ves-
selswrapped infoiland keptrefrigeratedbetweenuses.
Stocks of TPA were stored in the dark at -20°C over
Drierite.
Preparation ofAnimals and Methods of
Administration
Mice receiving single intraperitoneal (IP) injections
ofDMBA(300 ,ug) orurethane (20mg) asinitiatorswere
BALB/c
DmBA
BALB/c
DMBA .PA
...........
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FIGURE 1. Growth of female SENCAR and BALB/c mice exposed to DMBA and TPA.
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FIGURE 2. Survival of female SENCAR and BALB/c mice exposed to DMBA and TPA.
treated at 0 experimental time (7 weeks ofage). DMBA
(1200 ,ug/mL in DMSO/SSV), urethane (80 mg/mL in
saline), or the appropriate vehicle were given under a
portable charcoal-filtered lab hood byinjecting 0.25 mL/
mouse using 1-mL tuberculin syringes attached to ap-
propriate-sized hypodermic needles.
TPA solutions (12.5 R±g/mL or 6.25 pig/mL in acetone)
or acetone vehicle were applied topically to appropriate
groups at0.2mL, onceweekly, fromthefirstweekafter
initiationthroughthe 52nd experimental week. All mice
were shaved biweekly at least 24 hr before promotion
in a standardized area to expose the back skin to topi-
cally applied chemical treatments. Solutions were ap-
plied from Eppendorf multipipettes delivering 0.2 mL
Table 2. Tumor incidence in groups of 15 or 30 female SENCAR or BALB/c mice 52 weeks after intraperitoneal DMBA initiation and
with topical TPA promotion.
No. of SENCAR mice affected No. of BALB/c mice affected
(% of treatment group) (% of treatment group)
DSMO/ DMSO/ DMSO/ DMSO/
SSV/ SSV/ DMBA/ DMBA/ SSV/ SSV/ DMBA/ DMBA/
Tumor type or tissue acetonea TPAa acetoneb TPAb acetonea TPAa acetoneb TPAb
Skin 0 7 (47) 0 23 (76) 0 0 0 0
Papilloma 0 7 (47) 0 18 (60)a* 0 0 0 0
Cumulative no. per 0 0.8 0.1 4.2 0 0 0 0.03
initiated mouse
Carcinoma 0 1 (7) 0 17 (56)a* 0 0 0 0
Sarcoma 0 0 0 2 (6) 0 0 1 (3) 1 (3)
Lung 0 0 11 (36) 7 (23) 1 0 10 (33) 14 (46)
Ovary 0 0 4 (13) 2 (6) 0 0 4 (13) 2 (6)
Blood vessels 0 0 5 (16) 2 (6) 0 0 15 (50)* 20 (67)*
Uterine polypoid 0 0 1 (3) 0 1 0 5 (16) 6 (20)*
adenoma
Lymphoma 0 0 3 (10) 2 (6) 0 0 0 2 (6)
Mammary gland 0 1 (7) 2 (6) 2 (6) 0 0 0 0
carcinoma
Intestine 0 0 1 (3) 1 (3) 0 0 0 0
Histiocytic sarcoma 1 (7) 0 0 1 (3) 0 0 0 0
Any tumor 1 (7) 7 (47) 20 (67) 26 (86) 2/15 (13) 0 14 (80) 26 (86)
a 15 mice.
b30 mice.
*p < 0.05 vs. same group for other mouse strain.
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Table 3. Tumor incidence in female SENCAR and BALB/c mice 52 weeks after intraperitoneal urethane initiation and/or topical TPA
promotion.
No. of SENCAR mice with tumors No. of BALB/c mice with tumors
(% of treatment group) (% of treatment group)
Saline/ Urethane/ Urethane/ Saline/ Urethane/ Urethane/
Saline/ TPA acetone TPA Saline/ TPA acetone TPA
Tumor type or tissue acetone (n = 15)a (n = 29)' (n = 30)' acetone (n = 15)' (n = 30)' (n = 30)'
Skin 0 1 (7) 1 (3) 20 (67)C* 0 0 0 1 (3)
Papillomas 0 1 (7) 0 15 (50)C* 0 0 0 1
Cumulative no. per 0 0.4 0 1.9 0 0 0 0.03
initiated mouse
Carcinomas 0 0 1 (3) 12 (40)e* 0 0 0 0
Lung 1 (7) 1 (7) 18 (62) 24 (80) 2 (13) 2 (13) 26 (92)ab 29 (100)c
Blood vessels 0 0 2 (6) 1 (3) 0 0 9 (30)c* 7 (23)c*
Hemangioma 0 0 1 1 0 0 2 5
Hemangiosarcoma 0 0 1 0 0 0 7 2
Hematopoietic system 0 0 3 (10) 1 (3) 0 1 (7) 0 0
Forestomach 0 0 2 (6) 0 0 0 0 0
Uterus 0
Leiomyosarcoma 0 0 1 (3) 0 0 0 0 0
Polypoid adenoma 0 1 (7) 0 0 0 3 (20) 3 (10) 3 (10)
Histiocytic sarcoma 0 2 (13) 0 0 0 0 0 0
Any tumor 1 (7) 5 (33) 23 (79) 24 (80) 2 (13) 5 (36) 26 (87) 29 (97)
aNumber of mice examined.
bFrom 28 lungs available for histology.
'From 29 lungs available for histology.
*p < 0.05 vs. same group for other mouse strain.
FIGURE 3. Multiple skin papillomas and one carcinoma in a SEN-
CAR mouse initiated with DMBA and promoted by TPA.
of solution. Disposable tips were changed between
groups receiving TPA or vehicle. The concentration of
TPA stocks used from weeks 1 through 6 was 12.5 jig/
mL; 6.25 ,ug/mL was given from weeks 7 through 52.
Using these stocks resulted in doses of2.5 ,ug/mouse or
1.25 ,ug/mouse per week, respectively. The doses were
lowered when toxic skin reactions to TPA, which had
previously been shown to be progressive, were ob-
served.
Experimental Design
Table 1 summarizesthedesignation, composition, and
treatment for each group within this study. Mice were
weighedmonthly, andpapillomacountswereperformed
biweekly as previously described (3).
Pathology
Necropsieswereperformed onallanimalsfounddead,
on moribund mice euthanized during the study, and on
mice killed at termination (52 weeks) unless precluded
by autolysis or cannibalization. The following tissues
were routinely preserved in 10% formalin: skin, includ-
ing all malignant and benign tumors; any TPA-induced
skin lesions; and backskin, spleen, pancreas, lungs,
heart, thymus, trachea, larynx, thyroid, lung tumors,
kidneys and adrenals, liver, ovaries and uterus, brain,
pituitary, and grossly abnormal lymph nodes and other
lesions. Avidin-biotin peroxidase-complex (ABC) im-
munocytochemistry (6) was performed to localize ker-
atinin selected trypsinized skin tumors, surfactant apo-
protein (SAP) and Clara cell antigen (CCA) in lung
tumors by using rabbit antibodies to human keratin
(DAKO Corp., Santa Barbara, CA), specific antibodies
to SAP and CCA provided by Dr. G. Singh (6), and the
Vectastain kit (Vector Laboratories, Burlingame, CA).
64DIFFERENTIAL CARCINOGENIC EFFECTS
FIGURE 4. Squamous cellcarcinomaarisingwithinbaseofpapilloma
after exposure to DMBA and TPA. Hematoxylin and eosin, x 25.
Results
Body Weight and Survival
The growth of female SENCAR mice in all groups
was similar except for mice exposed to DMBA/TPA.
The latter mice gained weight at a considerably slower
rate than did other SENCAR mice (Fig. 1). BALB/c
mice ofall groups gained weight at the same rate (Fig.
1).
SENCAR mice exposed to DMBA/TPA also had
the worst survival rate (Fig. 2), since only 23% ofthe
mice survived to the end of the experiment, whereas
63% ofthe SENCAR mice receivingboth urethane and
TPA survived, and 77% to 100% ofthe SENCAR mice
in other groups survived. From 87% to 100% of the
BALB/c mice were alive at 52 weeks (Fig. 2).
Tumors in Control Mice
At 52weeksaftertreatment withtheinitiatorvehicle
(DMSO/SSVorsaline) andpromoter(TPA) orpromoter
vehicle (acetone) (59 weeks of age) skin and other tu-
mors were found in SENCAR or BALB/c mice (Tables
FIGURE 5. Keratin in poorly differentiated squamous cell carcinoma
after trypsin digestion of tissue section. ABC immunoperoxidase
and hematoxylin, x 250.
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FIGURE 6. Skin papillomas in female SENCAR mice initiated by20
,ug ofurethane intraperitoneally at 7 weeks of age and promoted
topically for 1-6 weeks later with TPA at 2.5 ,ug per mouse and
then 1.25 ,ug per mouse for weeks 7-52.
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Table 4. A comparison of gross and microscopic pulmonary lesions in female SENCAR and BALB/c mice 52 weeks after urethane
initiation and topical TPA promotion.
Saline/
acetone
(n = 15)'
SENCAR
Urethane/
acetone
(n = 29)a
Urethane/
TPA
(n = 30)'
Saline/
acetone
(n = 15)'
BALB/c
Urethane/
acetone
(n = 30)'
Urethane/
TPA
(n = 30)'
Lung tumors, grossly visible 7 (47) 17 (59) 24 (80) 1 (7) 26 (92) 26 (92)
Lung tumors, microscopic confirmation 1 (7) 18 (62) 24 (80) 2 (13) 26 (92) 29 (100)
Grossly visible lung nodules per mouse 1.3 ± 0.57 3.3 ± 0.79 4.3 ± 0.79 0.07 ± 0.07 4.5 ± 0.77 3.4 + 0.43
initiatedb
Microscopic confirmation-lung tumors 0.07 ± 0.07 2.1 ± 0.52 2.7 ± 0.5 0.13 ± 0.09 4.6 ± 0.71 4.4 ± 0.39
per mouse initiatedb
aNumber of mice examined.
bMean ± SEM.
Table 5. Histologic patterns of lung tumors in female SENCAR
and BALB/c mice initiated with urethane and topical TPA
promotion.
Number of tumors
(% of treatment group)
Tumor type SENCAR BALB/ca
All tumors 145 (100) 259 (100)
Alveolar, solid or mixed 68 (47) 79 (31)
Solid/tubular or tubular 32 (22) 71 (27)
Tubular/papillary or 45 (31) 109 (42)
papillary
aUrethane/acetone and urethane/TPA groups combined.
2 and 3). An increased incidence of skin tumors was
associated with TPA promotion in SENCAR mice after
DMSO/SSV vehicle initiation. In contrast, only a few
skin neoplasms were associated with TPA promotion
following saline vehicle initiation.
DMBA Initiation and TPA Promotion
DMBA/TPA-treated SENCAR mice that died early
in the study had many skin tumors as previously re-
ported (3) (Table 2). The occurrence of skin (Fig. 3),
vascular, and uterine tumors was strain-related (Table
2). In the DMBA/TPA-treated SENCAR mice, 17 mice
had 37 squamous cell carcinomas of the skin (10 seen
grossly), 3 ofwhich metastasized to lymph nodes and 2
to lungs. Several carcinomas were seen to arise within
papillomas (Fig. 4). Keratinwasfoundinwellandpoorly
differentiated carcinomas (Fig. 5). The vascular tumors
were usually small hemangiomas and were found in 35
of60BALB/cmiceandin7of60SENCARmiceexposed
to DMBA. In BALB/c mice, 57 vascular tumors were
found in 35 mice. These tumors usually involved the
serosa of intestines (18 mice), uterus (23), mesentery
(5), and other abdominal tissues (11). Uterine polypoid
adenomas were found more frequently in BALB/c mice
(11/60) than in SENCAR mice (1/60). Few skin tumors
were found in BALB/c mice. Other tumors were found
in similarincidences inboth strains, although mammary
and intestinal tumors were found only in SENCAR
mice. Control mice had few tumors of the skin, blood
vessels, and uterus. Lung tumors (adenomas or adeno-
FIGURE 7. Surfactant apoprotein in normal alveolar Type II cells
(bottom of figure) and in some tumor cells in solid-tubular pul-
monary adenoma induced by urethane. ABC immunoperoxidase
and hematoxylin, x 250.
carcinomas) occurred in higher incidence, whether con-
firmed microscopically (14/30 vs. 10/30) or counted vis-
ually (17/30 vs. 11/30), and in greater multiplicity (2.0
vs. 0.5), in BALB/c mice exposed to DMBA/TPA than
in BALB/c mice given DMBA alone. SENCAR mice
showed nodifferencesbetweenthese treatmentgroups.
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FIGURE 8. Surfactant apoprotein in vacuolated tumor cells in solid
areas of pulmonary adenoma and not in tubular focus. ABC im-
munoperoxidase and hematoxylin, x 250.
Urethane Initiation and TPA Promotion
In the urethane experiments, skintumors were found
primarily in SENCAR mice given urethane and TPA
(Fig. 6). Twelve mice had squamous cell carcinomas,
confirmed histologically, of which seven had been ob-
served clinically. Metastasis occurred in 5 ofthe 12mice
with squamous cell carcinoma; 4 had metastases to
lymph nodes and 2 to lungs. Vascular tumors were sig-
nificantly more common in BALB/c mice (16/60) than in
SENCAR mice (3/59). Most were hemangiosarcomas of
the uterus and peritoneal surfaces. Uterine polypoid
adenomas occurred primarily in BALB/c mice (6/60).
The occurrence oflungtumorsnotedbygrossinspection
was subjected to histologic confirmation (Table 4). The
number of microscopically visible lung tumors could
have actually been more numerous since only gross le-
sions were sectioned. The many gross nodules in saline-
treated SENCAR mice were found histologically to be
focal, chronic inflammatory lesions probably caused by
chronic Sendai infection, although these histological le-
sions were also seen in treated mice. Histologically,
tumors were identified as alveolar, solid, tubular, or
papillary adenomas and adenocarcinomas (Table 5). Dis-
FIGURE 9. Clara cell antigen in normal Clara cells in bronchiole
(lower left) but not in tubulopapillary pulmonary adenoma. ABC
immunoperoxidase and hematoxylin, x 250.
tribution oftumor types was not affected by treatment,
although more papillary tumors were seen in BALB/c
mice.
Selected representative lung tumors were evaluated
for the presence of pulmonary antigens. Immunocyto-
chemically, SAP was found in the cytoplasm of many
tumor cells of alveolar and solid lung tumors (Figs. 7
and 8) but in few cells oftubular and papillary tumors.
Rarely, tumor cell nuclei ofpapillary tumors contained
the antigen. CCA was never found in any lung tumors,
not even in papillary tumors (Fig. 9).
TPA application alone after using either of the two
vehicles caused a few skin papillomas and carcinomas
in SENCAR mice by 52 weeks (Tables 2 and 3).
Discussion
SENCAR mice were much more susceptible to two-
stage induction ofskin tumors than were BALB/c mice
as previously reported (3) but developed fewer carcin-
ogen-initiated vascular and uterine tumors than did
BALB/c mice. The increased susceptibility of BALB/c
mice to vascular tumors has been previously reported
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(7-9). The decreased susceptibility to these induced tu-
mors in SENCAR mice cannot be readily explained. It
was shown that metabolism of some carcinogens in se-
lected tissues does not differ significantly in these mice
(1), but theirincreased susceptibility to development of
skin tumors, however, may be related to the dark cell
population (2). Strains and stocks ofmice generally dif-
fer in their susceptibility to carcinogens because ofdif-
ferences in genetics, pharmacokinetics, background tu-
mor incidences, and other factors. The glomeru-
lonephritis and associated immunological lesions in our
SENCAR mice alter their responses to initiated cells,
preneoplastic lesions, or tumors (10). Skin tumors in-
duced by ultraviolet (UV) light have been found to be
associated with immunological dysfunction that may be
related to skin carcinogensis by chemicals (11). Since
SENCAR mice are also more susceptible to UV skin
carcinogenesis than other mouse strains, similar im-
munologic mechanisms may act in SENCAR mice. In-
ternal tumor development in these mice may not, how-
ever, dependsomuchonimmunologicalchanges (12,13).
No significant increase in lung carcinogenesis was
seen in either SENCAR mice initiated with urethane
and promoted with TPA orin BALB/cmice. It has been
reported that phorbol promotes lung tumors when ini-
tiated with dimethylnitrosamine (14). We may have ex-
pected a greater tumor incidence and multiplicity in
urethane/TPA-treated mice, but they died earlier than
the SENCAR mice treated only wvith urethane. Also,
Sendai virus infection, suggested in these mice by pul-
monaryinflammation, hasbeenshowntoreduceinduced
lung tumor incidence (15) and may have affected the
outcome of our experiment. Selected urethane-induced
lung tumors were usually immunoreactive for SAP, a
marker for alveolar Type II cells (6). Clara cell antigen
wasneverdetectedinanylungtumors, eveninpapillary
tumors, which have been suggested to be of Clara cell
origin (16).
The increased number of skin carcinomas seen his-
tologically over those found by clinical examination is
in agreement with the poor gross/microscopic correla-
tion seen in ourotherstudies. In two other studies with
topical DMBA and TPA, we found 24 carcinomas in 16
micehistologically, whereas only 6 were found clinically
in six mice. The ratio ofthree to four carcinomas found
histologically to every one identified by clinical exami-
nation appears to be consistent in our three studies. It
has been previously described (17) that squamous cell
carcinomas of the mouse skin arise within papillomas.
Thus, some ofthe early carcinomas arising within pap-
illomasareobviouslyseenclinicallyaspapillomas. Other
malignant lesions, however, can be mistaken for pa-
pillomas. It would be prudent to section all skin tumors
instudies when carcinoma developmentis acritical end-
point.
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